Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction.

BACKGROUND Effective endogenous fibrinolysis requires rapid release of tissue plasminogen activator (tPA) from the vascular endothelium. Smoking is a known risk factor for arterial thrombosis and myocardial infarction, and it causes endothelial dysfunction. We therefore examined the effects of cigarette smoking on substance P-induced tPA release in vivo in humans. METHODS AND RESULTS Blood flow and plasma fibrinolytic factors were measured in both forearms of 12 smokers and 12 age- and sex-matched nonsmokers who received unilateral brachial artery infusions of substance P (2 to 8 pmol/min). In both smokers and nonsmokers, substance P caused dose-dependent increases in blood flow and local release of plasma tPA antigen and activity (P<0.001 for all) but had no effect on the local release of plasminogen activator inhibitor type 1. Compared with nonsmokers, increases in forearm blood flow (P=0.03) and release of tPA antigen (P=0.04) and activity (P<0.001) caused by substance P were reduced in smokers. The area under the curve for release of tPA antigen and activity decreased by 51% and 53%, respectively. CONCLUSIONS Cigarette smoking causes marked inhibition of substance P-induced tPA release in vivo in humans. This provides an important mechanism whereby endothelial dysfunction may increase the risk of atherothrombosis through a reduction in the acute fibrinolytic capacity.

[1]  F. Feit,et al.  Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial. , 1989, Circulation.

[2]  B. Sobel,et al.  Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. , 1985, Circulation.

[3]  D. Webb,et al.  Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. , 1997, Clinical science.

[4]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[5]  C. Kluft,et al.  Effect of Chronic Smoking on Fibrinolysis , 1985, Arteriosclerosis.

[6]  V. Wynn,et al.  Variation in serum lipid and lipoprotein levels associated with changes in smoking behaviour in non-obese Caucasian males. , 1985, Atherosclerosis.

[7]  K. Isaaz,et al.  Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis. , 1996, Journal of the American College of Cardiology.

[8]  R. Virmani,et al.  Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. , 1997, The New England journal of medicine.

[9]  M Gent,et al.  Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.

[10]  J. Jansson,et al.  Predictive Value of Tissue Plasminogen Activator Mass Concentration on Long‐term Mortalit in Patients With Coronary Artery Disease A 7‐Year Follow‐up , 1993, Circulation.

[11]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[12]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[13]  E. Arnesen,et al.  Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. , 1996, Circulation.

[14]  K. Bürrig,et al.  The endothelium of advanced arteriosclerotic plaques in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  M. Sugimachi,et al.  Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. , 1994, Journal of the American College of Cardiology.

[16]  J. Gris,et al.  Venous occlusion and chronic cigarette smoking: dose-dependent decrease in the measurable release of tissue-type plasminogen activator and von Willebrand factor. , 1991, Atherosclerosis.

[17]  E. Braunwald,et al.  How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) , 1995, The American journal of cardiology.

[18]  D. Webb,et al.  An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium , 1997, Thrombosis and Haemostasis.

[19]  D. R. Gross,et al.  Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries , 1994, Neuropeptides.

[20]  R. Diaz,et al.  Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial , 1993, Circulation.

[21]  A. L'Abbate,et al.  Evidence for a systemic defect of resistance‐sized arterioles in hypertrophic cardiomyopathy , 1993, Coronary artery disease.

[22]  E. Brommer.  The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. , 1984, Thrombosis research.

[23]  J. Hung,et al.  Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. , 1995, Circulation.

[24]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[25]  R. Cannon,et al.  Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function? , 1987, The New England journal of medicine.

[26]  H. Just,et al.  Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. , 1996, Circulation.

[27]  J. Deanfield,et al.  Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. , 1996, The New England journal of medicine.

[28]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[29]  I. Holme,et al.  The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality. A 12‐year follow‐up of the Oslo Study, Norway , 1993, Journal of internal medicine.

[30]  L. Chen,et al.  Clinical factors and angiographic features associated with premature coronary artery disease. , 1995, Chest.

[31]  H. White,et al.  Significance of diabetes mellitus in patients with acute myocardial infraction receiving thrombolytic theraphy , 1993 .

[32]  D. Webb,et al.  The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. , 1998, Cardiovascular research.

[33]  T. Meade,et al.  Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study , 1993, The Lancet.

[34]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[35]  M. Olschewski,et al.  Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. , 1996, Circulation.

[36]  P. Mannucci.  Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. , 1997, Blood.

[37]  M. Davies.  The composition of coronary-artery plaques. , 1997, The New England journal of medicine.

[38]  P Vallance,et al.  Measuring forearm blood flow and interpreting the responses to drugs and mediators. , 1995, Hypertension.

[39]  J. Pepper,et al.  Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. , 1988, British heart journal.

[40]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[41]  R. Cannon,et al.  Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. , 1997, The New England journal of medicine.

[42]  C. Held,et al.  Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. , 1997, Circulation.

[43]  E. Barrett-Connor,et al.  Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. , 1997, Circulation.

[44]  Jeffrey L. Anderson,et al.  Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction , 1993 .

[45]  D. Webb,et al.  Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. , 1997, British journal of clinical pharmacology.

[46]  ÜRGEN,et al.  HEMOSTATIC FACTORS AND THE RISK OF MYOCARDIAL INFARCTION OR SUDDEN DEATH IN PATIENTS WITH ANGINA PECTORIS , 2001 .